Explanation
Tyrosinekinaseinhibitor
Imatinibwas originally developedforthetreatmemtof chronic myeloideukaemia,and isspecificforthe
tyrosinekinasescodedforbvthebcr-abutansocationc-kit) andtvrosinekinaseactivityrelatedothe
platelet-derived growthfactorreceptor.tisaisoutilised inthemanaqement ofgastrointestinat stromal
tumours.whicharedriven bvthesamefusionaene.
Common side-effects includeoedema,rash,nausea and musculoskeletaLpain.but patientsnormalyreport
theseasmid.Severecongestivecardiacfaiure isarareside-effect oftherapy
@1MINENDOCRINE
